APPLAUSE-IgAN (2025) — Trial Summary
APPLAUSE-IgAN (2025): This phase 3 trial evaluated iptacopan, an oral factor B inhibitor targeting the alternative complement pathway, in patients with IgA nephropathy, demonstrating the role of complement-mediated kidney injury in IgA nephropathy progression.
References
- Perkovic V, Barratt J, Rovin B, et al. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2025;392:531-543.